Interleukin 6 News and Research

RSS

Interleukin-6 (IL-6) is a protein that in humans is encoded by the "IL6" gene. IL-6 is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine. It is secreted by T cells and macrophages to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation.

Drug monitoring may provide alternative treatments for patients with severe H1N1

An international team of Canadian and Spanish scientists have found the first potential immunological clue of why some people develop severe pneumonia when infected by the pandemic H1N1 virus.

16 Dec 2009

Femta Pharmaceuticals, Lonza Group collaborate in cGMP production of FM101 antibody

Femta Pharmaceuticals and Lonza Group Ltd jointly announce the execution of a manufacturing services agreement to facilitate the development and cGMP manufacturing of FM101. FM101 is a high affinity monoclonal antibody in late pre-clinical development for the treatment of Rheumatoid Arthritis.

15 Dec 2009

RORalpha protein revealed as an essential regulator of inflammatory factors

How do the brain cells called astrocytes ensure the protection of neurons? By studying the protagonists in the protection and satisfactory functioning of neurons, scientists at the Laboratoire Neurobiologie des Processus Adaptatifs (CNRS/UPMC) have found a mechanism that clarifies the role of astrocytes.

15 Dec 2009

Update on new clinical developments and other initiatives related to Ceplene

EpiCept Corporation today provided an update on new clinical developments and other initiatives related to Ceplene® (histamine dihydrochloride), the Company’s therapy approved in the European Union for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia (AML) in first remission.

15 Dec 2009

Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in its Phase I/IIa clinical program evaluating the company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in combination with standard antiviral treatment and vaccination in HBeAg-negative chronic hepatitis B-infected (HBV) patients.

8 Dec 2009

Interleukin Genetics' PST genetic test approved for marketing in New York

Interleukin Genetics, Inc. announced today it has received approval by the State of New York's Department of Health for the Company to sell in New York its PST Genetic Test that determines predisposition to severe periodontal disease in individuals.

7 Dec 2009

Phase I/II clinical trial of Multimeric-001 Universal Flu Vaccine successful

BiondVax Pharmaceuticals Ltd., an Israeli biopharmaceutical company at the forefront of the development of a Universal Influenza Vaccine, announced the success of the Phase I/II clinical trial of the Company's Multimeric-001 Universal Flu Vaccine, in trials conducted at the Sourasky Medical Center in Tel Aviv, Israel.

7 Dec 2009

Lunasin may have important health benefits, two new studies report

Two new University of Illinois studies report that lunasin, a soy peptide often discarded in the waste streams of soy-processing plants, may have important health benefits that include fighting leukemia and blocking the inflammation that accompanies such chronic health conditions as diabetes, heart disease, and stroke.

3 Dec 2009

Study on the genetics of osteoarthritis

Interleukin Genetics, Inc. and NYU Langone Medical Center announced findings from a study performed in collaboration with Duke University on the genetics of osteoarthritis have been published this week in the "Online First" version of the Annals of Rheumatic Diseases and is available at http://ard.bmj.com/cgi/rapidpdf/ard.2009.113043v1.pdf.

2 Dec 2009

Human Melanoma Research Team pursuing identification of anti-tumor prognostic markers and drugs

The constant increase in the rate of cutaneous melanoma over recent years and its resistance to anti-tumour pharmaceutical drugs has meant that the study of cutaneous melanoma is one of the greatest scientific challenges in the field of cancer. The Human Melanoma research team at the University of the Basque Country (UPV/EHU) is focusing on this study.

2 Dec 2009

Discovery of Th22 cells may help in developing effective therapies for chronic skin and respiratory diseases

The newly discovered Th22 cells are a previously unknown subset of T helper cells. T helper cells are white blood cells that help activate other immune cells when the body is infected by viruses or bacteria. At the same time they help the body to tolerate own tissue and to prevent or curb inflammation.

20 Nov 2009

Patients with recent-onset schizophrenia have raised levels of inflammatory substances

Researchers at the Swedish medical university Karolinska Institutet have discovered that patients with recent-onset schizophrenia have higher levels of inflammatory substances in their brains. Their findings offer hope of being able to treat schizophrenia with drugs that affect the immune system.

18 Nov 2009

Th22 cell to control inflammation in body to help fight off infection discovered

A new type of immune cell that can be out of control in certain chronic inflammatory diseases, worsening the symptoms of conditions like psoriasis and asthma, is described for the first time in the Journal of Clinical Investigation.

17 Nov 2009

Researchers discover new immune mechanism against viruses

Viruses are microscopically sized parasites. They plant their genes in the cells of their victim in order to 'reprogram' them. The infected cells then no longer produce what they need to live, making lots of new viruses instead.

16 Nov 2009

Stelara expected to change dermatologists’ prescribing habits and alter patient flow models

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Centocor Ortho Biotech's Stelara, the first interleukin (IL)-12/23 inhibitor to enter the psoriasis drug market in the U.S., is expected to change the prescribing habits of dermatologists and substantially alter patient flow to currently marketed biologic agents, including Amgen's Enbrel and Abbott's Humira.

12 Nov 2009

Sanofi-aventis, Regeneron sign agreement to expand development collaboration

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today that they have entered into agreements to expand and extend their existing global collaboration to discover, develop, and commercialize fully-human therapeutic monoclonal antibodies.

11 Nov 2009

Bristol-Myers Squibb and Alder Biopharmaceuticals collaborate in development of novel biologic for rheumatoid arthritis

Bristol-Myers Squibb Company and Alder Biopharmaceuticals, Inc., today announced a global agreement for the development and commercialization of ALD518, a novel biologic that has completed Phase IIa development for the treatment of rheumatoid arthritis.

10 Nov 2009

EpiCept announces third quarter 2009 financial results

EpiCept Corporation today announced operating and financial results for the three and nine months ended September 30, 2009, and provided an update on Ceplene® and several of the Company’s key product candidates.

10 Nov 2009

New biosensor device may help in combating cancer

A powerful new biosensor developed by European researchers will help identify cells in the immune system that actively suppress tumour growth, then put them to use. Enlisting the patient's own immune system would be like sending reinforcements for resistance fighters.

5 Nov 2009

Survey shows majority of rheumatologists would prescribe Actemra drug for rheumatoid arthritis

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 98 percent of surveyed rheumatologists indicate they will prescribe Roche's Actemra, an interleukin-6 inhibitor, for the treatment of rheumatoid arthritis following the agent's expected launch in 2010.

4 Nov 2009

Interleukin 6 News and Research

Further Reading

Drug monitoring may provide alternative treatments for patients with severe H1N1

Femta Pharmaceuticals, Lonza Group collaborate in cGMP production of FM101 antibody

RORalpha protein revealed as an essential regulator of inflammatory factors

Update on new clinical developments and other initiatives related to Ceplene

Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced

Interleukin Genetics' PST genetic test approved for marketing in New York

Phase I/II clinical trial of Multimeric-001 Universal Flu Vaccine successful

Lunasin may have important health benefits, two new studies report

Study on the genetics of osteoarthritis

Human Melanoma Research Team pursuing identification of anti-tumor prognostic markers and drugs

Discovery of Th22 cells may help in developing effective therapies for chronic skin and respiratory diseases

Patients with recent-onset schizophrenia have raised levels of inflammatory substances

Th22 cell to control inflammation in body to help fight off infection discovered

Researchers discover new immune mechanism against viruses

Stelara expected to change dermatologists’ prescribing habits and alter patient flow models

Sanofi-aventis, Regeneron sign agreement to expand development collaboration

Bristol-Myers Squibb and Alder Biopharmaceuticals collaborate in development of novel biologic for rheumatoid arthritis

EpiCept announces third quarter 2009 financial results

New biosensor device may help in combating cancer

Survey shows majority of rheumatologists would prescribe Actemra drug for rheumatoid arthritis

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News